Poly-Arginine Peptide R18D Reduces Infarct Volume by 47.2% in Rat Ischemic Stroke Model
Background
Ischemic stroke remains a leading cause of death and long-term disability, with limited therapeutic options, primarily thrombolysis, which has a narrow therapeutic window. Current treatments often fail to mitigate the extensive neuronal damage and inflammation that occur post-reperfusion. Developing neuroprotective agents that can extend this window and reduce infarct size is crucial. Peptides like R18D, with their potential to cross the blood-brain barrier and exert direct neuroprotective effects, are being investigated to address this critical gap in stroke management.
Study Design
Researchers investigated the dose-dependent efficacy and pharmacokinetics of R18D in a rat transient middle cerebral artery occlusion (MCAO) model. R18D was administered intravenously (IV) 60 min after the onset of a 90-min MCAO induced by intraluminal filament insertion. Three doses were tested: 325 nmol/kg, 650 nmol/kg, and 1100 nmol/kg. Blood samples were collected for pharmacokinetic profiling at various time points up to 8 h after a 10-min IV infusion. Primary endpoints included infarct volume and cerebral hemisphere swelling, assessed at 24 h post-MCAO, alongside body weight changes.
Results
R18D demonstrated significant neuroprotective effects, reducing mean total infarct volume across all tested doses. The most pronounced reduction was observed with the 325 nmol/kg dose, which cut infarct volume by 47.2% (p = 0.0003). Higher doses also showed efficacy, with 650 nmol/kg reducing infarct volume by 28.4% (p = 0.008) and 1100 nmol/kg by 27.9% (p = 0.003).
Key Findings
- R18D reduced mean total infarct volume by 47.2% (p = 0.0003) at 325 nmol/kg.
- The 650 nmol/kg dose of R18D significantly reduced cerebral hemisphere swelling by 8.3% (p = 0.01).
- R18D exhibited a half-life of 72 to 78 min across tested doses in post-stroke rats.
- Dose-dependent plasma Cmax values ranged from 5.3 μg/mL to 17.3 μg/mL.
Why It Matters
This study provides strong evidence that R18D could be a promising neuroprotective agent for ischemic stroke, potentially extending the therapeutic window beyond current limitations. The finding that R18D is effective even when administered 60 minutes post-stroke onset is particularly significant, as it suggests a wider treatment window compared to existing thrombolytic therapies. For future clinical translation, these pharmacokinetic data (half-life of 72-78 min) are vital for designing optimal dosing regimens. This research supports continued development of R18D, potentially leading to novel protocols for acute stroke management that could significantly improve patient outcomes by reducing brain damage.
r18d
ischemic stroke
neuroprotection
poly-arginine
animal study
pharmacokinetics